Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 479

1.

Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells.

Ko JC, Ciou SC, Jhan JY, Cheng CM, Su YJ, Chuang SM, Lin ST, Chang CC, Lin YW.

Mol Cancer Res. 2009 Aug;7(8):1378-89. doi: 10.1158/1541-7786.MCR-09-0051. Epub 2009 Aug 11.

2.

Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells.

Tsai MS, Kuo YH, Chiu YF, Su YC, Lin YW.

J Pharmacol Exp Ther. 2010 Dec;335(3):830-40. doi: 10.1124/jpet.110.173146. Epub 2010 Sep 20.

PMID:
20855443
3.

Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells.

Ko JC, Hong JH, Wang LH, Cheng CM, Ciou SC, Lin ST, Jheng MY, Lin YW.

Mol Cancer Ther. 2008 Nov;7(11):3632-41. doi: 10.1158/1535-7163.MCT-08-0578.

4.

Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells.

Ko JC, Ciou SC, Cheng CM, Wang LH, Hong JH, Jheng MY, Ling ST, Lin YW.

Carcinogenesis. 2008 Jul;29(7):1448-58. doi: 10.1093/carcin/bgn130. Epub 2008 Jun 9.

PMID:
18544565
5.

Curcumin enhances the mitomycin C-induced cytotoxicity via downregulation of MKK1/2-ERK1/2-mediated Rad51 expression in non-small cell lung cancer cells.

Ko JC, Tsai MS, Weng SH, Kuo YH, Chiu YF, Lin YW.

Toxicol Appl Pharmacol. 2011 Sep 15;255(3):327-38. doi: 10.1016/j.taap.2011.07.012. Epub 2011 Jul 24.

PMID:
21810436
6.

Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation.

Chen RS, Jhan JY, Su YJ, Lee WT, Cheng CM, Ciou SC, Lin ST, Chuang SM, Ko JC, Lin YW.

Exp Cell Res. 2009 Sep 10;315(15):2658-72. doi: 10.1016/j.yexcr.2009.06.002. Epub 2009 Jun 6.

PMID:
19505457
7.

Role of Rad51 down-regulation and extracellular signal-regulated kinases 1 and 2 inactivation in emodin and mitomycin C-induced synergistic cytotoxicity in human non-small-cell lung cancer cells.

Su YJ, Tsai MS, Kuo YH, Chiu YF, Cheng CM, Lin ST, Lin YW.

Mol Pharmacol. 2010 Apr;77(4):633-43. doi: 10.1124/mol.109.061887. Epub 2009 Dec 30.

PMID:
20042515
8.
9.

Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells.

Ko JC, Chiu HC, Syu JJ, Jian YJ, Chen CY, Jian YT, Huang YJ, Wo TY, Lin YW.

Biochem Pharmacol. 2014 Mar 1;88(1):119-27. doi: 10.1016/j.bcp.2014.01.010. Epub 2014 Jan 18.

PMID:
24447935
10.

The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells.

Ko JC, Wang LH, Jhan JY, Ciou SC, Hong JH, Lin ST, Lin YW.

Lung Cancer. 2009 Sep;65(3):290-8. doi: 10.1016/j.lungcan.2008.12.008. Epub 2009 Jan 20.

PMID:
19157634
11.

HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells.

Ko JC, Chen HJ, Huang YC, Tseng SC, Weng SH, Wo TY, Huang YJ, Chiu HC, Tsai MS, Chiou RY, Lin YW.

Regul Toxicol Pharmacol. 2012 Dec;64(3):415-24. doi: 10.1016/j.yrtph.2012.10.003. Epub 2012 Oct 13.

PMID:
23069143
12.

Resveratrol Enhances Etoposide-Induced Cytotoxicity through Down-Regulating ERK1/2 and AKT-Mediated X-ray Repair Cross-Complement Group 1 (XRCC1) Protein Expression in Human Non-Small-Cell Lung Cancer Cells.

Ko JC, Syu JJ, Chen JC, Wang TJ, Chang PY, Chen CY, Jian YT, Jian YJ, Lin YW.

Basic Clin Pharmacol Toxicol. 2015 Dec;117(6):383-91. doi: 10.1111/bcpt.12425. Epub 2015 Jun 30.

13.

Modulation of Rad51, ERCC1, and thymidine phosphorylase by emodin result in synergistic cytotoxic effect in combination with capecitabine.

Ko JC, Tsai MS, Kuo YH, Chiu YF, Weng SH, Su YC, Lin YW.

Biochem Pharmacol. 2011 Mar 1;81(5):680-90. doi: 10.1016/j.bcp.2010.12.008. Epub 2010 Dec 17.

PMID:
21168393
14.

Minocycline enhances mitomycin C-induced cytotoxicity through down-regulating ERK1/2-mediated Rad51 expression in human non-small cell lung cancer cells.

Ko JC, Wang TJ, Chang PY, Syu JJ, Chen JC, Chen CY, Jian YT, Jian YJ, Zheng HY, Chen WC, Lin YW.

Biochem Pharmacol. 2015 Oct 1;97(3):331-40. doi: 10.1016/j.bcp.2015.07.025. Epub 2015 Jul 23.

PMID:
26212550
15.

Up-regulation of extracellular signal-regulated kinase 1/2-dependent thymidylate synthase and thymidine phosphorylase contributes to cisplatin resistance in human non-small-cell lung cancer cells.

Ko JC, Tsai MS, Chiu YF, Weng SH, Kuo YH, Lin YW.

J Pharmacol Exp Ther. 2011 Jul;338(1):184-94. doi: 10.1124/jpet.111.179663. Epub 2011 Mar 28.

PMID:
21444628
16.

The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells.

Chen MC, Chen CH, Wang JC, Tsai AC, Liou JP, Pan SL, Teng CM.

Cell Death Dis. 2013 Sep 19;4:e810. doi: 10.1038/cddis.2013.330.

17.

Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.

Sano Y, Hashimoto E, Nakatani N, Abe M, Satoh Y, Sakata K, Fujii T, Fujimoto-Ouchi K, Sugimoto M, Nagahashi S, Aoki M, Motegi H, Sasaki E, Yatabe Y.

Mol Cancer Ther. 2015 Feb;14(2):533-41. doi: 10.1158/1535-7163.MCT-14-0456. Epub 2014 Dec 18.

19.

EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.

Phuchareon J, McCormick F, Eisele DW, Tetsu O.

Proc Natl Acad Sci U S A. 2015 Jul 21;112(29):E3855-63. doi: 10.1073/pnas.1510733112. Epub 2015 Jul 6.

20.

Down-regulation of ERK1/2 and AKT-mediated X-ray repair cross-complement group 1 protein (XRCC1) expression by Hsp90 inhibition enhances the gefitinib-induced cytotoxicity in human lung cancer cells.

Tung CL, Jian YJ, Syu JJ, Wang TJ, Chang PY, Chen CY, Jian YT, Lin YW.

Exp Cell Res. 2015 May 15;334(1):126-35. doi: 10.1016/j.yexcr.2015.01.016. Epub 2015 Feb 4.

PMID:
25662161

Supplemental Content

Support Center